Type 2 Diabetes | CHOP Research Institute

In the News: Mitochondrial Disease, ALL, Type 2 Diabetes, Sleep Apnea

Published on

Sep 16, 2022

This week’s In the News highlights research on mitochondrial disease, acute lymphoblastic leukemia, type 2 diabetes, and sleep apnea.

Center for Spatial and Functional Genomics

The Center for Spatial and Functional Genomics is focused on uncovering the correct functional context of variants identified by genome-wide association studies in order to translate these discoveries into meaningful benefits for pediatric care.

Spatial and Functional Genomics Research Affinity Group

Uncovering the correct functional context of genetic variants to translate genome-wide association studies into meaningful benefits for pediatric care.

In The News: COVID Breathalyzer, Distinguished Career Awardee, Kids’ COVID Vaccine, Youth-Onset Type 2 Diabetes, Mental Health and Greenspace

Published on

Aug 6, 2021

in Cornerstone Blog

This week’s research news features Dr. Audrey Odom John and her discovery of six breath compounds that could lead to a COVID breathalyzer for kids.

Ertugliflozin for Children and Adolescents with Type 2 Diabetes

You are invited to take part in a voluntary research trial because you have type 2 diabetes and are between the ages of 10 and 17 years.

Roizen Laboratory

The Roizen Lab aims to understand non-calciometabolic vitamin D effects and to use this understanding to design new therapies for common diseases like sarcopenia and obesity.

Canagliflozin in Children with Type 2 Diabetes

The goal of this study is to investigate the efficacy and safety of Canagliflozin (which is experimental) in children and adolescents ages 10 to 18 years old with Type 2 diabetes and poor control (i.e., an HbA1c of 6.5% to 10.5%).

Steven M. Willi, MD

Dr. Willi's research focuses on therapeutics for type 1 and type 2 diabetes and he has performed a number of physiologic studies in the etiology and characterization of diabetes in children. His current studies include trials on the delay of progression of type 1 diabetes and a multicenter trial to examine the optimal therapeutics for type 2 diabetes in children.

E-mail:

willi [at] chop.edu

Rebecca A. Simmons, MD

The principal goal of Dr. Simmons' research program is to elucidate the underlying molecular mechanisms that link an aberrant intrauterine milieu to the later development of diseases in adulthood. She has made many seminal contributions to the understanding of the role that epigenetic modifications play in developmental programming of obesity and type 2 diabetes.

E-mail:

simmonsr [at] chop.edu

Lorraine L. Katz, MD

Dr. Katz’s investigates the sequelae of obesity and type 2 diabetes mellitus in youth. Her research involves the intersection of sleep, obesity, and glucose intolerance and prevention of cardiovascular risk. Her studies have led to the evaluation of quantitative tools important for assessment of metabolic risk in youth.

E-mail:

katzl [at] chop.edu